Experimental evidence suggests that platelets contribute to metastasis through adhesive and haemostatic functions that promote cancer cell survival, immune evasion and interactions with vascular cells to assist organ colonization from the bloodstream. Extensive experimental evidence shows that platelets support tumour metastasis. The activation of platelets and the coagulation system have a crucial role in the progression of cancer. Within the circulatory system, platelets guard tumour cells from immune elimination and promote their arrest at the endothelium, supporting the establishment of secondary lesions. These contributions of platelets to tumour cell survival and spread suggest platelets as a new avenue for therapy.

Contribution of platelets to tumour metastasis.

Tumours display considerable variation in the patterning and properties of angiogenic blood vessels, as well as in their responses to anti-angiogenic therapy. Angiogenic programming of neoplastic tissue is a multidimensional process regulated by cancer cells in concert with a variety of tumour-associated stromal cells and their bioactive products, which encompass cytokines and growth factors, the extracellular matrix and secreted microvesicles. In this Review, we discuss the extrinsic regulation of angiogenesis by the tumour microenvironment, highlighting potential vulnerabilities that could be targeted to improve the applicability and reach of anti-angiogenic cancer therapies.

Microenvironmental regulation of tumour angiogenesis

Platelet α–granules: Basic biology and clinical correlates

Blood platelets have long been recognised to bring about primary haemostasis with deficiencies in platelet production and function manifesting in bleeding while upregulated function favourises arterial thrombosis. Yet increasing evidence indicates that platelets fulfil a much wider role in health and disease. First, they store and release a wide range of biologically active substances including the panoply of growth factors, chemokines and cytokines released from a-granules. Membrane budding gives rise to microparticles (MPs), another active participant within the blood stream. Platelets are essential for the innate immune response and combat infection (viruses, bacteria, micro-organisms). They help maintain and modulate inflammation and are a major source of pro-inflammatory molecules (e.g. P-selectin, tissue factor, CD40L, metalloproteinases). As well as promoting coagulation, they are active in fibrinolysis; wound healing, angiogenesis and bone formation as well as in maternal tissue and foetal vascular remodelling. Activated platelets and MPs intervene in the propagation of major diseases. They are major players in atherosclerosis and related diseases, pathologies of the central nervous system (Alzheimers disease, multiple sclerosis), cancer and tumour growth. They participate in other tissue-related acquired pathologies such as skin diseases and allergy, rheumatoid arthritis, liver disease; while, paradoxically, autologous platelet-rich plasma and platelet releasate are being used as an aid to promote tissue repair and cellular growth. The above mentioned roles of platelets are now discussed.

Platelets, inflammation and tissue regeneration

https://www.cell.com/cancer-cell/pdf/S1535-6108(15)00349-9.pdf

RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics

Platelets actively sequester angiogenesis regulators

Platelet-associated PF-4 as a biomarker of early tumor growth

Platelet-associated PF-4 as a biomarker of early tumor growth. Commentary

The present invention relates to the fields of immunology and biochemistry. Particularly, the present invention describes methods, devices and kits for early detection of clinical conditions having associated changes in systemic angiogenic activity, particularly cancers, inflammatory conditions, infections, and events associated with pregnancy and abortion.

Platelet biomarkers for cancer

L'invention concerne les domaines de l'immunologie et de la biochimie. Elle concerne, en particulier, des methodes, des dispositifs et des trousses servant a effectuer la detection precoce d'etats cliniques auxquels sont associees des modifications de l'activite angiogene systemique, en particulier, des cancers, des etats inflammatoires, des infections ou des evenements associes a la grossesse et a l'avortement.

Vladimir N. Podust

Papers

Platelets actively sequester angiogenesis regulators

Platelet-associated PF-4 as a biomarker of early tumor growth

Platelet-associated PF-4 as a biomarker of early tumor growth. Commentary

Platelet biomarkers for cancer

Biomarqueurs de plaquettes servant a detecter le cancer